Expanded Collaboration Between Incyte Corp. and Specialised Therapeutics to Advance Opzelura in Australia
In a recent development, Incyte Corp. has broadened its collaborative framework with Specialised Therapeutics, an independent specialty pharmaceutical firm. The expanded agreement will see the two companies jointly advance the commercialisation, regulatory registration and distribution of ruxolitinib cream, marketed as Opzelura, in the Australian market.
Under the new arrangement, Incyte will continue to oversee the development and manufacturing of the topical Janus kinase inhibitor, while Specialised Therapeutics will assume responsibility for local regulatory submissions, medical affairs, marketing and distribution activities.
The partnership, which originally began in 2021, is now positioned to extend Incyte’s presence into the dermatology sector, where the cream has already received approvals for the treatment of non‑segmental vitiligo and mild to moderate atopic dermatitis in several major markets. The decision reflects a strategic focus on conditions that impose significant physical and psychosocial burdens on patients, and on the broader aim of delivering innovative therapies to communities with unmet needs.
Both parties highlighted the complementary strengths that underpin the collaboration. Incyte’s expertise in product development and manufacturing aligns with Specialised Therapeutics’ track record of navigating complex regulatory and commercial environments across Australia, New Zealand and Southeast Asia. The companies anticipate progressing local regulatory and reimbursement submissions for Opzelura in the coming months, with the goal of ensuring timely and equitable access for Australian patients.
Overall, the expanded partnership underscores Incyte Corp.’s commitment to expanding its portfolio and geographic reach, while reinforcing its operational alignment with a partner experienced in delivering specialty therapies across diverse regions. The move is expected to strengthen the availability of Opzelura in Australia and may signal further opportunities for Incyte’s portfolio in emerging therapeutic areas.
